Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Black Diamond Therapeutics, Inc. - Common Stock (NQ:BDTX)

2.870 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Black Diamond Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Black Diamond (BDTX) Q2 Loss Narrows 47%
Via The Motley Fool
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Looking Into Black Diamond Therapeutic's Recent Short Interest
 
Via Benzinga
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
These stocks have an unusual volume in today's session
These stocks have an unusual volume in today's session 
Via Chartmill
Unusual volume stocks in Thursday's session
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
These stocks are the most active in today's session
These stocks are making the most noise in today's session. Stay tuned for the latest updates! 
Via Chartmill
What's going on in today's session
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High
As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer. 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Wednesday's session: gap up and gap down stocks
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million
Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an upfront payment of $70 million and up to $710 million in milestone... 
Via Benzinga
Discover the top movers in Wednesday's pre-market session.
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements
Via AB Newswire
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows... 
Via Benzinga
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
From Gyre Therapeutics, Inc.
Via GlobeNewswire
BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q2 2024
BDTX stock results show that Black Diamond Therapeutic beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.